Effect of Injectable Platelet Rich Derivatives on Orthodontic Canine Retraction

February 10, 2026 updated by: Yusra Ali Al Shawri, Sana'a University

The Effect of Injectable Platelet Rich Derivatives on the Rate of Orthodontic Canine Retraction: A Split-Mouth Randomized Controlled Trial

This study evaluated the effect of injectable platelet-rich derivatives on the rate of orthodontic canine retraction. Patients requiring orthodontic canine retraction following premolar extraction were enrolled and divided into three groups using a split-mouth design. Injectable platelet-rich plasma (PRP) and platelet-rich fibrin (PRF) were applied to compare their effects on the rate of tooth movement. The outcomes were assessed by measuring the amount of canine retraction over time.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

21

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Yemen
      • Sanaa, Yemen
        • Faculty of Dentistry, Sana'a University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Healthy individuals aged 17-29 years (mean age 24 ± 6 years)
  • Diagnosis of Class I bimaxillary protrusion or Class II division 1 requiring first premolar extractions
  • Full permanent dentition
  • Good oral hygiene
  • Non-smokers
  • Not taking medications affecting bone metabolism (e.g., bisphosphonates)

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Contraindications to platelet therapies (e.g., platelet dysfunction)
  • Severe malocclusion unsuitable for fixed appliances
  • Dental anomalies (size/shape)
  • Systemic syndromes

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PRP vs Control (Split-Mouth)
Split-mouth group in which one side received platelet-rich plasma (PRP) injection and the contralateral side served as a control without injection during orthodontic canine retraction.
Biological: Platelet-Rich Plasma (PRP)
Autologous platelet-rich plasma prepared from the patient's own blood and injected locally at the experimental side to accelerate orthodontic canine retraction.
Experimental: PRF vs Control (Split-Mouth)
Split-mouth group in which one side received platelet-rich fibrin (PRF) injection and the contralateral side served as a control without injection during orthodontic canine retraction.
Biological: Platelet-Rich Fibrin (PRF)
Autologous platelet-rich fibrin prepared from the patient's own blood and injected locally to accelerate orthodontic canine retraction.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of Orthodontic Canine Retraction
Time Frame: From baseline (initiation of orthodontic canine retraction) until completion of canine retraction, assessed monthly for up to 4 months.
The amount of orthodontic canine movement measured in millimeters.
From baseline (initiation of orthodontic canine retraction) until completion of canine retraction, assessed monthly for up to 4 months.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sana'a University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 30, 2024

Primary Completion (Actual)

September 5, 2024

Study Completion (Actual)

September 5, 2024

Study Registration Dates

First Submitted

January 26, 2026

First Submitted That Met QC Criteria

February 10, 2026

First Posted (Actual)

February 13, 2026

Study Record Updates

Last Update Posted (Actual)

February 13, 2026

Last Update Submitted That Met QC Criteria

February 10, 2026

Last Verified

February 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • SU-DENT-001

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Individual participant data will not be shared because this study was conducted as part of a master's degree thesis and the data are subject to institutional and ethical restrictions.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Accelerate Tooth Movement

Clinical Trials on Platelet-Rich Plasma (PRP)

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe